저침습 녹내장 수술 기기 시장 : 메커니즘, 적응증, 수술 접근, 최종사용자, 유통 채널별 - 세계 전망(2025-2030년)

The Minimally Invasive Glaucoma Surgery Devices Market was valued at USD 612.65 million in 2024 and is projected to grow to USD 647.08 million in 2025, with a CAGR of 5.76%, reaching USD 857.80 million by 2030.

A concise orientation to how minimally invasive glaucoma surgery devices are reshaping clinical decision-making and procedural pathways across care settings

Minimally invasive glaucoma surgery devices are redefining therapeutic pathways for glaucoma by offering less disruptive surgical alternatives that emphasize safety, faster recovery, and iterative adoption across clinical settings. Recent device innovations and evolving surgeon preferences have accelerated the re-evaluation of care algorithms, driving attention from ophthalmic leaders, ambulatory operators, and clinical innovators. This introduction frames the convergence of technological refinement, clinical evidence development, and evolving delivery models that together shape adoption trajectories and commercial priorities.

The clinical impetus for minimally invasive approaches stems from the demand to reduce reliance on chronic topical therapies, mitigate procedural risk, and expand treatment options earlier in disease pathways. As techniques have matured, stakeholders have responded by reconfiguring surgical workflows, redefining training pathways, and integrating multidisciplinary teams to manage perioperative care. Consequently, decision makers must balance device selection, surgeon training, and facility readiness alongside reimbursement realities and patient expectations.

Transitioning from procedural innovation to broader adoption requires clarity on comparative performance, ease of integration, and real-world outcomes. This introduction sets the stage for a comprehensive examination of how mechanism, indication, surgical approach, end user, and distribution dynamics influence strategic choices across manufacturers, healthcare systems, and clinical practices.

How evolving device designs, site-of-care migration, and payer expectations are converging to rewrite competitive dynamics and clinical decision pathways

The landscape for minimally invasive glaucoma surgery devices is undergoing transformative shifts driven by technological refinement, clinical evidence accumulation, and operational redesign across care sites. Device evolution has moved beyond single-point improvements to a systems-level rethinking of how pressure modulation is achieved, how devices are delivered, and how outcomes are measured, thereby prompting clinicians and administrators to reassess treatment sequencing and care pathways.

Concurrently, the locus of care is shifting as ambulatory surgery centers scale procedures that were once hospital-bound, while ophthalmic clinics expand pre- and post-operative management capabilities. This redistribution of procedure volume is supported by streamlined device profiles that reduce intraoperative complexity and postoperative follow-up demands. Alongside clinical adoption, payer dialogues have evolved to focus on value, total cost of care, and patient-reported outcomes, increasing pressure on manufacturers to demonstrate tangible improvements in safety and quality metrics.

Moreover, innovation ecosystems have broadened: partnerships between device developers, surgical training organizations, and digital-health platforms are enabling faster surgeon onboarding and outcome tracking. In parallel, a more fragmented supplier base, including nimble startups and strategic alliances with established medical device companies, is intensifying competition and accelerating feature differentiation. Together, these forces are redefining competitive advantage in a market where clinical relevance, commercial scalability, and the ability to demonstrate value to payers and providers determine long-term success.

Qualitative assessment of how the 2025 United States tariff measures reshaped supply chains, sourcing strategies, and commercial contracting across the device value chain

The policy environment introduced by United States tariffs announced in 2025 has created a material set of operational and strategic implications for participants in the minimally invasive glaucoma surgery device ecosystem. While tariffs are typically characterized as trade policy levers, their cumulative effect has rippled across supply chains, sourcing strategies, and commercial pricing decisions. Manufacturers with globalized procurement footprints have had to reassess supplier portfolios to preserve margin and ensure continuity of component availability.

Faced with increased input costs and potential delays, many device developers accelerated efforts to diversify their supplier base and identify near-shore or onshore manufacturing alternatives. This transition, however, involves lead times for qualification, regulatory transfer activities, and capital allocation decisions that can affect product timelines. For downstream stakeholders such as distributors and health systems, the tariff-driven adjustments manifested as shifts in negotiated pricing and inventory management tactics, including higher buffer stocks for critical implants and consumables.

Importantly, tariffs also influenced strategic route-to-market choices. Some manufacturers prioritized direct distribution in key regions to control margin erosion and pricing signaling, while others intensified collaboration with regional partners to mitigate tariff exposure. For clinicians and patients, the practical consequences have been uneven across settings: ambulatory centers and clinics operating on tighter procurement cycles felt pricing pressure earlier, while hospitals with longer contracting horizons absorbed changes more gradually. Overall, the 2025 tariffs catalyzed a reassessment of supply chain resilience, manufacturing location strategy, and commercial contracting practices across the value chain.

Segment-driven insights explaining how mechanism, clinical indication, surgical approach, care setting, and distribution dynamics determine adoption and positioning

Segment-level dynamics reveal how mechanism, indication, surgical approach, end user, and distribution channel each create distinct competitive and clinical pathways that manufacturers and providers must navigate. Based on Mechanism, the market is studied across Subconjunctival Filtration, Suprachoroidal Shunts, and Trabecular Micro-Bypass; within Trabecular Micro-Bypass, specific device variations such as Hydrus Microstent, IStent, Kahook Dual Blade, and Trabectome illustrate how design differentiation affects implantation technique and postoperative management. This mechanistic granularity helps explain divergent adoption curves, since devices that minimize tissue disruption and shorten operative times are more readily integrated into ambulatory settings.

Based on Indication, the market is studied across Pediatric Glaucoma, Primary Open Angle Glaucoma, and Secondary Glaucoma, and these clinical subpopulations demand distinct evidence packages and training approaches. Pediatric indications require long-term safety data and specialized instrumentation, whereas primary open angle glaucoma presentations prioritize combination therapy strategies and minimally disruptive options for earlier intervention. Secondary glaucoma cases often necessitate tailored solutions that address complex anatomy or prior surgical history, influencing device selection and surgeon preference.

Based on Surgical Approach, the market is studied across Ab Externo and Ab Interno, with the latter gaining traction due to reduced invasiveness and faster patient recovery, while ab externo techniques remain relevant for certain anatomical contexts. Based on End User, the market is studied across Ambulatory Surgery Centers, Hospital, and Ophthalmic Clinics, each with different procurement cycles, staffing models, and reimbursement frameworks that shape product positioning. Based on Distribution Channel, the market is studied across Offline and Online pathways, where digital platforms are increasingly important for clinician education, device ordering, and aftermarket support. Together, these segmentation lenses provide a multidimensional view of strategic priorities and practical constraints for product development, commercialization, and clinical adoption.

Regional implications for regulatory engagement, commercialization, and clinician adoption across Americas, Europe Middle East & Africa, and Asia-Pacific geographies

Regional dynamics are reshaping investment priorities, regulatory engagement, and commercial execution across distinct geographies, each presenting unique opportunities and constraints. In the Americas, innovation hubs, concentrated payer dialogues, and a high density of ambulatory surgery centers create an environment that favors devices which deliver predictable outcomes and can be scaled through established distribution networks. Regulatory pathways and reimbursement negotiations in this region often reward robust clinical evidence and value-based narratives.

In Europe, Middle East & Africa, fragmentation of regulatory regimes and heterogeneity in hospital procurement models require adaptive commercialization strategies. Manufacturers operating in this region benefit from modular clinical programs that can address varying evidence thresholds and from partnerships that support localized training and post-market surveillance. Price sensitivity in many markets coexists with centers of clinical excellence that serve as influential early adopters.

In Asia-Pacific, rapid capacity expansion in specialty ophthalmic centers, evolving reimbursement frameworks, and a large patient base drive diverse adoption scenarios. Local manufacturing and strategic licensing partnerships are prominent approaches to address regulatory nuances and cost expectations. Moreover, regional centers often become focal points for clinical trials and training initiatives that support broader commercialization across neighboring markets. Taken together, regional nuances demand tailored regulatory, clinical, and commercial roadmaps to optimize product uptake and long-term sustainability.

How varied company strategies - from incumbent portfolio plays to startup-led disruption - shape commercialization, evidence generation, and competitive positioning

Company-level strategies reveal a spectrum of behaviors that reflect differing risk appetites, resource endowments, and strategic priorities. Many established medical device firms focus on incremental device enhancements, scaling surgeon training programs, and leveraging existing sales channels to accelerate penetration in ambulatory and hospital settings. These incumbents often emphasize portfolio integration, bundling of perioperative services, and payer engagement to embed devices within care pathways.

Simultaneously, innovative smaller firms and startups are concentrating on disruptive device concepts, differentiated delivery mechanisms, and targeted clinical evidence to enter niche indications or surgical subsegments. These innovators frequently adopt agile development cycles, collaborate with specialized surgical centers for early feasibility studies, and pursue targeted regulatory strategies to expedite market entry. Strategic partnerships between larger firms and these innovators are increasingly common, enabling faster commercialization of novel technologies while mitigating development risk.

Across the competitive spectrum, companies prioritize three interlocking capabilities: clinical evidence generation that aligns with payer value metrics, scalable distribution and training models that lower adoption friction, and supply chain resilience that minimizes exposure to geopolitical shifts. Organizations that excel across these dimensions tend to be those that invest early in robust post-market data collection, cultivate strong clinician champions, and design commercial models that reflect the procedural economics of ambulatory and hospital environments.

Practical strategic moves manufacturers, supply chain leaders, clinicians, and payers can deploy to accelerate adoption and insulate operations from policy and market shocks

Actionable priorities emerge for leaders seeking to convert insights into measurable outcomes in clinical adoption, commercial traction, and operational resilience. Manufacturers should prioritize building modular evidence packages that address both clinical endpoints and payer-relevant value metrics, while simultaneously designing training curricula that reduce surgeon learning curves and facilitate uptake in ambulatory settings. Investment in post-market surveillance and real-world evidence platforms will help strengthen reimbursement arguments and maintain provider confidence.

Supply chain leaders must accelerate dual-sourcing strategies and evaluate near-shore manufacturing options to reduce exposure to tariff-induced cost shocks and logistics disruptions. Contracting teams should renegotiate terms with an eye to flexibility, incorporating volume-based tiers and shorter re-pricing windows to respond to rapid policy shifts. For distributors and health systems, aligning procurement cadence with device lifecycle stages and developing contingency inventory plans will preserve access and protect patient scheduling.

Clinician leaders and hospital administrators should collaborate to define clear patient selection criteria, standardize perioperative care pathways, and measure patient-reported outcomes to demonstrate comparative value. Finally, cross-sector stakeholders are advised to pursue targeted pilot programs that combine device deployment with economic modeling and outcomes tracking to catalyze payer discussions and build local evidence for broader adoption.

A rigorous, multi-source research approach combining primary clinical interviews, regulatory review, and iterative validation to ensure analytical reliability

The research methodology underpinning this analysis integrates triangulated evidence drawn from primary stakeholder engagement, targeted secondary review, and systematic validation protocols. Primary inputs included structured interviews with surgeons, operating room managers, procurement leaders, and device developers, designed to surface on-the-ground insights about device selection, procedural logistics, and reimbursement dynamics. These interviews were complemented by observational inputs from procedure workflows and training sessions to capture practical integration challenges that may not be visible in published literature.

Secondary research encompassed regulatory documentation, peer-reviewed clinical literature, and public filings to map device approvals, indications, and clinical endpoints. Where regulatory documents were limited, corroborative interviews and procedural observations helped contextualize approval timelines and post-market obligations. Data synthesis involved cross-referencing clinical outcomes with distribution patterns and procurement practices to identify consistent trends and outliers.

Quality assurance was maintained through iterative review cycles with domain experts, triangulation across independent sources, and a clear statement of limitations where data gaps exist. The methodology emphasizes transparency in provenance and reproducibility of analytical steps, and notes that while effort was made to incorporate a diverse set of perspectives, local regulatory idiosyncrasies and proprietary commercial arrangements may require supplemental, context-specific investigation for transactional decisions.

Synthesis of strategic imperatives emphasizing clinical relevance, supply chain resilience, and targeted evidence generation to secure long-term adoption

This executive summary synthesizes the strategic contours that now define minimally invasive glaucoma surgery devices: technological diversification across mechanisms, evolving clinical adoption across indications and surgical approaches, and the increasing importance of regionalized commercialization strategies. Stakeholders that align product design with pragmatic clinician needs, invest in outcome-focused evidence, and build resilient, flexible supply chains are best positioned to capture durable value.

The cumulative policy and market shifts of recent years have underscored the need for agility. Providers and manufacturers must continuously reassess operating assumptions in light of tariff exposure, shifting site-of-care economics, and payer expectations for demonstrated value. Importantly, the most successful strategies will integrate clinical, commercial, and operational levers-pairing device differentiation with scalable training, targeted evidence generation, and adaptive contracting.

Looking forward, the interplay between clinical innovation and distribution innovation will determine which technologies become standard of care and which remain niche. Companies and health systems that invest early in collaborative pilots, robust real-world evidence programs, and surgeon enablement will create the conditions for sustained adoption and improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Rapid rise in combined cataract and ab interno MIGS procedures for glaucoma management leading to streamlined surgical workflows
• 5.2. Commercial launch of drug-eluting suprachoroidal microstents offering sustained intraocular pressure control without daily drops
• 5.3. Growing surgeon preference for trabecular meshwork bypass stents driven by simplicity and favorable safety profile in early glaucoma
• 5.4. Increasing investment in smart intraoperative imaging integration to enhance precision of MIGS device placement and procedural outcomes
• 5.5. Expansion of reimbursement coverage for office-based MIGS treatments improving patient access in key developed markets
• 5.6. Development of next-generation bioresorbable implants aimed at reducing foreign body reactions and long-term tissue scarring
• 5.7. Surge in clinical trials evaluating combination therapies of MIGS devices with sustained-release pharmacologics for enhanced efficacy
• 5.8. Entry of emerging-market manufacturers offering cost-competitive MIGS alternatives spurring pricing pressure on established players

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Minimally Invasive Glaucoma Surgery Devices Market, by Mechanism

• 8.1. Introduction
• 8.2. Subconjunctival Filtration
• 8.3. Suprachoroidal Shunts
• 8.4. Trabecular Micro-Bypass
  • 8.4.1. Hydrus Microstent
  • 8.4.2. IStent
  • 8.4.3. Kahook Dual Blade
  • 8.4.4. Trabectome

9. Minimally Invasive Glaucoma Surgery Devices Market, by Indication

• 9.1. Introduction
• 9.2. Pediatric Glaucoma
• 9.3. Primary Open Angle Glaucoma
• 9.4. Secondary Glaucoma

10. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Approach

• 10.1. Introduction
• 10.2. Ab Externo
• 10.3. Ab Interno

11. Minimally Invasive Glaucoma Surgery Devices Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgery Centers
• 11.3. Hospital
• 11.4. Ophthalmic Clinics

12. Minimally Invasive Glaucoma Surgery Devices Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
• 12.3. Online

13. Americas Minimally Invasive Glaucoma Surgery Devices Market

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. Argentina

14. Europe, Middle East & Africa Minimally Invasive Glaucoma Surgery Devices Market

• 14.1. Introduction
• 14.2. United Kingdom
• 14.3. Germany
• 14.4. France
• 14.5. Russia
• 14.6. Italy
• 14.7. Spain
• 14.8. United Arab Emirates
• 14.9. Saudi Arabia
• 14.10. South Africa
• 14.11. Denmark
• 14.12. Netherlands
• 14.13. Qatar
• 14.14. Finland
• 14.15. Sweden
• 14.16. Nigeria
• 14.17. Egypt
• 14.18. Turkey
• 14.19. Israel
• 14.20. Norway
• 14.21. Poland
• 14.22. Switzerland

15. Asia-Pacific Minimally Invasive Glaucoma Surgery Devices Market

• 15.1. Introduction
• 15.2. China
• 15.3. India
• 15.4. Japan
• 15.5. Australia
• 15.6. South Korea
• 15.7. Indonesia
• 15.8. Thailand
• 15.9. Philippines
• 15.10. Malaysia
• 15.11. Singapore
• 15.12. Vietnam
• 15.13. Taiwan

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Alcon Inc.
  • 16.3.2. Ellex Medical Lasers Ltd.
  • 16.3.3. AbbVie Inc.
  • 16.3.4. Bausch+Lomb France SAS
  • 16.3.5. Carl-Zeiss AG
  • 16.3.6. Corza Ophthalmology
  • 16.3.7. Glaukos Corporation
  • 16.3.8. I Optima Ltd.
  • 16.3.9. Iridex Corporation
  • 16.3.10. iSTAR Medical
  • 16.3.11. Johnson & Johnson Vision Care, Inc.
  • 16.3.12. Lumenis Be Ltd.
  • 16.3.13. New World Medical, Inc.
  • 16.3.14. Optonol Ltd.
  • 16.3.15. Santen Pharmaceutical Co., Ltd.
  • 16.3.16. Sight Sciences, Inc.
  • 16.3.17. Ziemer Ophthalmic Systems AG

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix